Gedeon Richter Plc.
http://www.richter.hu
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Gedeon Richter Plc.
Lebrikizumab Among Nine Drugs To Get EMA Nod; PTC Faces Disappointment For Translarna
The European Medicines Agency has OKd nine new medicines for EU-wide approval, but recommended against renewing the conditional marketing authorization of two drugs.
Uzbekistan To Implement Large Pharma Projects
Uzbekistan is the most populous country in Central Asia with 36 million people. The country has the only plant in Central Asia specializing in insulin production for the treatment of diabetes. Uzbek authorities aim to develop 90 pharma projects worth $1.2bn by 2026.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances
Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.
AbbVie’s Blockbuster Vraylar Adds Significant Indication, Adjunctive MDD
Already selling at a run rate above $2bn annually, AbbVie predicts the atypical antipsychotic could reach the $4bn mark with a new US indication for adjunctive treatment of major depressive disorder.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
-
- PregLem Holding SA
- Richter Gedeon Vegyeszeti Gyar Nyrt
- Richter-Helm BioTec GmbH
- FINOX Biotech
- Finox AG
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice